Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AVETUX-CRC phase II trial of avelumab + cetuximab + FOLFOX in untreated metastatic colorectal cancer
2016-004434-26Phase 2Completed
- Sponsor
- AIO-Studien
- Start
- Dec 2016
- Modality
- Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of avelumab, cetuximab, oxaliplatin, fluorouracil and folinic acid in metastatic colorectal adenocarcinoma (mCRC), sponsored by AIO-Studien. Primary endpoint: Progression-free survival rate at 12 months. Started Dec 2016; status: completed.
02
Drugs
avelumabcetuximaboxaliplatinfluorouracilfolinic acid
03
Conditions
metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on 2016-004434-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004434-26.